Company Filing History:
Years Active: 2016-2021
Title: Innovations and Contributions of Yuval Avnir
Introduction
Yuval Avnir is a notable inventor based in Boston, MA, who has made significant contributions to the field of immunology. With a total of three patents to his name, Avnir's work focuses on the development of innovative solutions for enhancing immune responses, particularly in relation to influenza and other viral infections.
Latest Patents
Avnir's latest patents include groundbreaking inventions such as "Immunogenetic restriction on elicitation of antibodies." This invention provides structural determinants that are crucial for binding to the stem domain of the HA protein of the influenza virus. It also outlines methods for producing high-affinity neutralizing antibodies against the influenza virus based on these determinants. Furthermore, this patent offers tools for assessing the efficacy of influenza virus vaccines and provides a molecular signature that can predict immunologic exposure or responsiveness to vaccines or infections.
Another significant patent is titled "Humanized monoclonal antibodies and methods of use." This invention features a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene VH1-69. Derived from Mab G6, this antibody recognizes the same epitope and is designed to be used in conjunction with vaccines to enhance immune responses to specific antigens.
Career Highlights
Yuval Avnir is currently affiliated with the Dana-Farber Cancer Institute Inc., where he continues to advance his research and innovations in immunology. His work has been instrumental in developing new therapeutic approaches that leverage the body's immune system to combat diseases.
Collaborations
Avnir collaborates with esteemed colleagues such as Wayne A. Marasco and Jianhua Sui, who contribute to his research endeavors and help further the impact of his inventions in the scientific community.
Conclusion
In summary, Yuval Avnir's contributions to immunology through his patents and research at the Dana-Farber Cancer Institute Inc. highlight his commitment to advancing medical science and improving vaccine efficacy. His innovative work continues to pave the way for new therapeutic strategies in the fight against viral infections.